MRPMedical Research and Practice2993-96902993-9704Art and Technology10.61369/MRP.2026090018ArticleKMSC-Exos 联合中医药改善急性肾损伤研究进展https://artdesignp.com/journal/MRP/4/9/10.61369/MRP.2026090018赵梓安,葛亮,梁政亭,段沐含,梁瑞宁2026492026-09-20急性肾损伤（Acute Kidney Injury,AKI）应归入临床危重症类，其诱因很多、病理过程较复杂，目前尚缺少针对病因的精确干预及特异药物疗法。以肾脏间充质干细胞为来源的外泌体（KMSC-Exos）是新出现的生物治疗形式，所具有的低免疫原性及组织趋化性对再生有较大意义，但体内靶向效率的提高仍是其临床应用的主要障碍。现将有关肾脏间充质干细胞（KMSCs）及所释外泌体治疗AKI 的研究做一归纳性总结，对KMSC-Exos 修复AKI 的机制作初步分析；同时提出用该类疗法配合中医药治疗AKI 的可能性，希望由此找到突破AKI 转化难题的全新思路。急性肾损伤,肾脏间充质干细胞,外泌体,IL-17信号通路

[1]Chen J, Xu X, Cai Y, et al. Acute kidney injury over the past decade: from definition evolution to pathogenesis insights and innovative therapeutic strategies. Cell Mol LifeSci. 2026 Mar 6;83(1):156.[2]Liang RN, Yan DQ, Zhang XP, et al. Kidney Mesenchymal stem cells alleviate cisplatin-induced kidney injury and apoptosis in rats. Tissue Cell. 2023 Feb;80:101998.[3]Gomez J, Schmeckpeper J, Mirotsou M. Transcriptomic Analysis of Adult Renal Derived Mesenchymal Stem-Like Cells. Methods Mol Biol. 2016;1416:495-507.[4]Trigo CM, Rodrigues JS, Camões SP, et al. Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? J Adv Res. 2025 Apr;70:103-124.[5]Lotfy A, AboQuella NM, Wang H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. 2023 Apr 7;14(1):66.[6]Wang JJ, Zheng Y, Li YL, et al. Emerging role of mesenchymal stem cell-derived exosomes in the repair of acute kidney injury. World J Stem Cells. 2025 Mar26;17(3):103360.[7]Wan Y, Yu Y, Yu C, et al. Human umbilical cord mesenchymal stem cell exosomes alleviate acute kidney injury by inhibiting pyroptosis in rats and NRK-52E cells. Ren Fail.2023 Dec;45(1):2221138.[8]Liu M, Chen X. Human Umbilical Cord-Derived Mesenchymal Stem Cells-Exosomes-Delivered miR-375 Targets HDAC4 to Promote Autophagy and Suppress T CellApoptosis in Sepsis-Associated Acute Kidney Injury. Appl Biochem Biotechnol. 2024 Nov;196(11):7954-7973.[9]Wang SY, Xu Y, Hong Q, et al. Mesenchymal stem cells ameliorate cisplatin-induced acute kidney injury via let-7b-5p. Cell Tissue Res. 2023 May;392(2):517-533.[10]Xie Z, Tang J, Chen Z, et al. Human bone marrow mesenchymal stem cell-derived extracellular vesicles reduce inflammation and pyroptosis in acute kidney injury viamiR-223-3p/HDAC2/SNRK. Inflamm Res. 2023 Mar;72(3):553-576.Copyright © This Work is Licensed under A Commons Attribution-Non Commercial 4.0 International License. | 125[11]Yang Q, Zhang YL, Chen SJ, et al.Targeting CH25H/25HC-ferroptosis axis: a novel mechanism of MSC-EVs mediated renoprotection in ischemic AKI. JNanobiotechnology. 2026 Apr 9.[12]Peng F, Chen X, Wu L, et al. Nitric oxide-primed engineered extracellular vesicles restore bioenergetics in acute kidney injury via mitochondrial transfer. Theranostics.2025 Apr 13;15(11):5499-5517.[13]McGeachy MJ, Cua DJ, Gaffen AS. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019 Apr 16;50(4):892-906.[14]Liu W, Hu C, Zhang B, et al. Exosomal microRNA-342-5p secreted from adipose-derived mesenchymal stem cells mitigates acute kidney injury in sepsis mice byinhibiting TLR9. Biol Proced Online. 2023 Apr 21;25(1):10.[15]Deng WJ, Tang R, Ma MQ, et al. AMSC-EVs attenuate acute kidney injury through TXNIP-IKKα/NFκB signaling-mediated renal CX3CR1+ macrophage polarization.Stem Cell Res Ther. 2025 Nov 14;16(1):639.[16]Cheng R, Tian RM, Huang LH, et al. [Effect and mechanism of Jiedu Huoxue Decoction in regulating YAP/ACSL4 pathway to inhibit ferroptosis in treatment of acutekidney injury]. Zhongguo Zhong Yao Za Zhi. 2024 Jan;49(1):151-161. Chinese.[17]Wu JJ, Zhang TY, Qi YH, et al. Efficacy and safety of Yiqi Peiyuan granules for improving the short-term prognosis of patients with acute kidney injury: A multicenter,double-blind, placebo-controlled, randomized trial. J Integr Med. 2024 May;22(3):279-285.[18] 卫荣, 温欣, 王莉, 等. 中药补肾活血方提取物促进SD 大鼠骨髓间充质干细胞增殖作用的最佳浓度[J]. 中国组织工程研究,2019,23(5):691-696.[19]Wan X, Xu P, Zhou X, et al. Qi-Gu capsule alleviates osteoporosis by inhibiting mesenchymal stem cell senescence via the HIF-1α/AMPK axis. Phytomedicine. 2025Jul;142:156764.[20] 本期专题: 中药促进骨髓间充质干细胞的增殖与分化[J]. 中国组织工程研究,2012,16(19):3411+3592+3601.[21]Wu J, Ge Y, Huang W, et al. Natural bioactive compounds modified with mesenchymal stem cells: new hope for regenerative medicine. Front Bioeng Biotechnol. 2025 May9;13:1446537.[22]Wang F, Qian H, Kong L, et al. Accelerated Bone Regeneration by Astragaloside IV through Stimulating the Coupling of Osteogenesis and Angiogenesis. Int J Biol Sci.2021 Apr 24;17(7):1821-1836.[23]Ceccotti E, Saccu G, Herrera Sanchez MB, et al. Naïve or Engineered Extracellular Vesicles from Different Cell Sources: Therapeutic Tools for Kidney Diseases.Pharmaceutics. 2023 Jun 12;15(6):1715.[24]Lee SA, Yoo TH. Therapeutic application of extracellular vesicles for various kidney diseases: a brief review. BMB Rep. 2022 Jan;55(1):3-10.[25]Chen B, Chen J, Shen Z, et al. Curcumin pretreatment enhances the capacity of BMSC exosomes to attenuate renal ischemia-reperfusion injury by ferroptosis suppressionvia miR-16-5p/Smad3/Mb axis. Stem Cell Res Ther. 2026 Feb 9;17(1):110.[26]Yu JB, Shi J, Zhang Y, et al. Electroacupuncture Ameliorates Acute Renal Injury in Lipopolysaccharide-Stimulated Rabbits via Induction of HO-1 through the PI3K/Akt/Nrf2 Pathways. PLoS One. 2015 Nov 2;10(11):e0141622. doi: 10.1371/journal.pone.0141622. PMID: 26524181; PMCID: PMC4629879.[27]Krueger JP, Robles M, Whedon J, et al. Management of Acute Kidney Injury with Ayurveda, Acupuncture, and Chinese Herbal Medicine: A Case Report. Med Acupunct.2025 Aug 8;38(3):235-239. doi: 10.1177/19336586251366995. PMID: 42130693; PMCID: PMC13158463.[28]Navez M, Detry O, Jouret F. Mesenchymal/stromal cell therapy in kidney diseases: an update. Curr Opin Nephrol Hypertens. 2026 Jul 1;35(4):465-472.[29]Zhang Z, She L, Bai M. Efficacy of exosomes in acute kidney injury treatment and the associated mechanism (Review). Mol Med Rep. 2025 May;31(5):137.